Alpha Teknova, Inc.
TKNOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAlpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The $396.1M market capitalization puts TKNO squarely in small-cap range for its industry. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Market Cap
$396.1M
Beta
0.86
P/E (TTM)
—
P/E (Fwd)
-33.79
EPS (TTM)
$-0.32
EPS (Fwd)
$-0.19
ROE
-24.2%
ROA
-9.3%
Cash
$17.4M
Total Debt
$27.4M
Free CF
-$735,250
52W Change
13.0%
Annual Financials
Cash vs Debt
Where TKNO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TKNO finished 25.93% above its 150-day moving average ($5.40) and 43.16% above its 200-day moving average ($4.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TKNO overbought or oversold?
At the October 20, 2026 close, TKNO's RSI(14) was 16.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $17.4M in cash, though total debt stands at $27.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$735K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -24.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $41.4M (2022) to $40.5M (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alpha Teknova, Inc.'s trajectory.